CNS 2a Withdrawn Phase 1 Trials for MK-1775 (DB11740)

IndicationStatusPhase
DBCOND0085877 (CNS 2a)Withdrawn1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02791919Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid LeukemiaTreatment